April 9(Reuters) - Takara Bio Inc <4974.T>:Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takara's NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies.
Sept 27 (Reuters) - Takara Bio Inc <4974.T>:* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26 .
Takara Bio Inc <4974.T> : Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively . Says units Rubicon Genomics and WaferGen Bio-systems will be dissolved after transaction .Says the company, Takara Bio Inc, is a consolidated subsidiary of Takara Holdings Inc <2531.T>.
Wafergen Bio-systems Inc <WGBS.O>: Wafergen Bio-systems reports revenue growth in fourth quarter of 2016 . Sees FY 2016 revenue about $10.7 million . Wafergen Bio-Systems Inc - company expects total revenue for Q4 of 2016 to be approximately $3.9 million or a 62% increase .Wafergen Bio-Systems Inc - ended Q4 with cash of approximately $4.5 million, which includes initial $2.5 million advanced by Takara Bio USA Holdings, Inc.
Takara Bio Inc <4974.T>:Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma.
Takara Bio Inc <4974.T> : Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time) .Previous plan was disclosed on Dec. 15, 2016.
Takara Bio Inc <4974.T>: Says its unit Takara Bio USA Holdings Inc plans to acquire Rubicon Genomics, Inc in early Jan. 2017 .Says transaction price expected at $75 million.
Takara Bio <4974.T>: Says it signed an exclusive license agreement of Oncolytic virus HF10 with Otsuka Pharmaceutical .Says it gives development and sale right of HF10 to Otsuka Pharmaceutical.
WaferGen Bio-systems Inc <WGBS.O>: Wafergen Bio-Systems announces stockholder approval of merger with Takara Bio .Wafergen Bio-Systems Inc - "look forward" to closing transaction in Q1 of 2017.
Takara Bio Inc <4974.T> :Launch of fully differentiated, Cellartis hiPS beta cells for research use.